Dr. Perez on the Antibody-Drug Conjugate T-DM1

Edith A. Perez, MD
Published: Wednesday, Feb 13, 2013

Edith A. Perez, MD, deputy director, Mayo Clinic Cancer Center, Florida, director, Breast Program, Serene M. and Frances C. Durling Professor of Medicine, Mayo Medical School, discusses the antibody-drug conjugate T-DM1 (trastuzumab emtansine) that is being investigated as a treatment for patients with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

Perez believes T-DM1 is a marvelous drug and is glad that she was able to be involved in its development process. She notes that overall survival data from the phase III EMILIA trial showed a significant advantage for T-DM1 compared to the lapatinib plus capecitabine. In the trial, overall survival was 30.9 months for T-DM1 compared to 25.1 months. These results, Perez states, are practice changing and were the basis for FDA approval in February 2013 (Find out more).

Overall, Perez feels that T-DM1 is a very important agent that further stresses the utility of antibody-drug conjugates. The goal of these agents, Perez states, is to combine a targeted therapy with chemotherapy in order to minimize toxicity while increasing efficacy, which is accomplished with T-DM1.

Edith A. Perez, MD, deputy director, Mayo Clinic Cancer Center, Florida, director, Breast Program, Serene M. and Frances C. Durling Professor of Medicine, Mayo Medical School, discusses the antibody-drug conjugate T-DM1 (trastuzumab emtansine) that is being investigated as a treatment for patients with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

Perez believes T-DM1 is a marvelous drug and is glad that she was able to be involved in its development process. She notes that overall survival data from the phase III EMILIA trial showed a significant advantage for T-DM1 compared to the lapatinib plus capecitabine. In the trial, overall survival was 30.9 months for T-DM1 compared to 25.1 months. These results, Perez states, are practice changing and were the basis for FDA approval in February 2013 (Find out more).

Overall, Perez feels that T-DM1 is a very important agent that further stresses the utility of antibody-drug conjugates. The goal of these agents, Perez states, is to combine a targeted therapy with chemotherapy in order to minimize toxicity while increasing efficacy, which is accomplished with T-DM1.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x